Biotechnology Last month, Peregrine Pharmaceuticals (Nasdaq: PPHM) announced the discovery of "major data discrepancies" between reported results and patient treatment code assignments for its randomized, double-blind, Phase IIb clinical trial investigating bavituximab as second-line treatment in stage IIIb and IV non-small cell lung cancer (NSCLC) patients (The Pharma Letter September 25). Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is believed to trigger vascular disruption, and enhance antitumor and antiviral immune responses. 17 October 2012